[ 1 ] Li Y Y, Zhang T, Schwartz S J, et al. New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential[J]. Drug Resistance Updates, 2009, 12(1/2): 17-27. [2]Sidera K, Patsavoudi E. HSP90 inhibitors: Current development and potential in cancer therapy[J]. Recent Patents on Anti-Cancer Drug Discovery, 2013, 9(1): 1-20. [3]Alarcon S V, Mollapour M, Lee M J, et al. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy[J]. Current Molecular Medicine, 2012, 12(9): 1125-1141. [4]张钟元, 阎爱侠. Hsp90抑制剂的研究进展[J]. 中国医药生物技术, 2021, 16(1): 41-50. [5]Shrestha L, Bolaender A, Patel H J, et al. Heat shock protein (HSP) drug discovery and development: Targeting heat shock proteins in disease[J]. Current Topics in Medicinal Chemistry, 2016, 16(25): 2753-2764. [6]Liu N X, Chen Q H, Zhang Q Q, et al. The application of prodrug-based drug delivery strategy in anticancer drugs[J]. Current Topics in Medicinal Chemistry, 2021, 21(24): 2184-2204. [7]Zawilska J B, Wojcieszak J, Olejniczak A B. Prodrugs: A challenge for the drug development[J]. Pharmacological Reports, 2013, 65(1): 1-14. [8]Zhang T, Yang X R, Xu W P, et al. Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy[J]. Cancer Biology & Medicine, 2021, 18(3): 693-704. [9]Daneri-Becerra C, Galigniana M D. The Hsp90-binding immunophilin FKBP52 enhances neurodifferentiation and neuroregeneration in murine models[J]. Neural Regeneration Research, 2022, 17(3): 555-556. [10]林智才, 陈燕丽, 苏小清, 等. Hsp90抑制剂减弱肝癌耐药细胞株对索拉非尼诱导铁死亡的耐受性[J]. 现代肿瘤医学, 2022, 30(21): 3862-3868.
[1]李敏,曹慧,钱文斌. Hsp90抑制剂BIIB021对人急性T细胞白血病Molt4细胞周期和凋亡的影响[J].浙江理工大学学报,2012,29(04):589.
LI Min,CAO Hui,QIAN Web bin.Effects of Hsp90 Inhibitor BIIB021 on Apoptosis and Cell Cycle inHuman TCell Acute Lymphocytic Leukemia Cell Line Molt4[J].Journal of Zhejiang Sci-Tech University,2012,29(自科五):589.
作者简介: 刘文金(1995-),男,甘肃天水人,硕士研究生,主要从事有机物合成方面的研究
通信作者: 曹小冬,E-mail: sheldon.cao@eubulusbio.com